عنوان

33rd Hemophilia Symposium :

3642182607

9783642182600

b567143

33rd Hemophilia Symposium :

[Book]

Hamburg 2002

edited by Inge Scharrer, Wolfgang Schramm.

Berlin ; New York

Springer

©2004.

(324 pages)

HIV Infection and Causes of Death in Patients with Hemophilia in Germany (Year 2001/2002 Survey) --; Hemophilia Registry of the Medical Committee of the Swiss Hemophilia Association --; Annual Survey 2002 --; "New Viruses" and the Safety of Factor Concentrates and Stable Blood Products: TT Virus and West Nile Virus as Current Examples --; A Retrospective Study on the Development of Inhibitors after Continuous Infusion of Factor VIII --; Characterization of Factor VIII-Inhibitory Antibodies Using Phage Display --; Rituximab --; A new Treatment of Acquired Hemophilia A? --; Thrombin Generation and Thrombogram: Assays for Monitoring Factor VIII Bypassing Therapies --; Rehabilitation --; A Topic for Hemophiliacs? --; Functional Analysis as a Basis for Optimizing Physiotherapy in Hemophilic Children --; Sport and Physical Fitness Recommendations for Young Hemophiliacs --; Pain Versus Clinical and Radiological Assessment in Hemophilic Arthropathies --; Endogenous Thrombin Potential in Platelet-Rich Plasma --; New Insights Regarding the Different Action of F VIII and F IX --; Interactive and Case-Based Training of Diagnostic Skills and Therapeutical Management of Coagulation Disorders with CAMPUS, a Computer-Based Program --; Elevated Fibrinogen is a Risk Factor for Arterial Thrombosis in Children --; Increased von-Willebrand-Factor-Binding to Platelets in Neonatal Plasma --; Neonatal Protein C Deficiency after massive thromboembolic Event of the right upper Limb Treatment with Protein C Concentrate --; IMMUNATE S/D --; A new Factor VIII --; von-Willebrand-Factor Complex Concentrate --; Favorable Response to Protein C in Venoocclusive Disease after Allogeneous Stem Cell Transplantation --; Phase III Clinical Evaluation of rAHF-PFM Prepared Using a Plasma/Albumin free Method --; Anti-Prionin IgG, Possible new Serum Markers for Contact and Infection with Transmissible Spongiform Encephalopathies: Preliminary Results from Screening 100 Blood Donors --; Experimental Approaches to Hemophilia Gene Therapy: Gene Transfer into Hematopoietic Stem Cells --; Von-Willebrand-Factor Cleaving Protease (ADAMTS-13) Activity in Various Thrombotic, Hemolytic and Autoimmune Disorders --; Treatment with Interferon Alpha-2a in Patients with Hepatitis C and Hemophilia --; Practical Experiences with Therapies for Chronic Hepatitis C in Hemophilia Patients --; Deep Venous Thrombosis of the Lower Extremity in a 16-Year-old Girl with Homozygous MTHFR- and Heterozygous Factor V Leiden-Mutation --; Clinical Manifestations of Patients with Highly Elevated Anticardiolipin Antibodies --; Progression of an Extensive Deep Vein Thrombosis Under High Dose Therapy with low Molecular Weight Heparin of a 13-4 Year-old Girl Suffering from Colitis Ulcerosa --; Hyperfibrinolysis in Hemophagocytic Lymphohistiocytosis --; Prolonged Lysis-Therapy of an Arteria Iliaca Externa Thrombosis in a very low Birth Weight Infant with a Variant in the Factor-XIII-Gene --; Modified Immunsuppression in a Case of Acquired Hemophilia --; Case Report --; Life-Threatening Bleeding after Vaccination as a First Manifestation of Hemophilia A --; Administration of Protein C-Concentrate (Ceprotin, Baxter) in Purpura Fulminans as the First Clinical Manifestation of Galactosemia --; Case Report: Successful Treatment of a Spontaneous Acquired Inhibitor against Factor VIII in a 73-Year old Patient --; Medical Need and Quality of Life in Patients with Hemophilia A --; Quality of Life Autoevaluation of Hemophilia Patients in Romania --; Valproate-Induced Type I von-Willebrand's Disease --; a Common Occurrence? --; Bleeding Symptoms in Carriers of Hemophilia A --; Association to the Factor VIII Gene Mutation? --; Recombinant Human Interferon?-2b Therapy, for Refractory Immune Thrombocytopenic Purpura in Children --; Review on Bleeding Episodes in Hemophiliacs Receiving no Primary Prophylactic Replacement Therapy --; Endogenous Thrombin Potential and Thrombin Activatable Fibrinolysis Inhibitor in Patients with Hemophilia and von-Willebrand Disease --; Different Thrombotic Risk Factors --; Contribution to the Endogenous Thrombin Potential --; Coagulation Parameters in Pregnancy: Low-Molecular-Weight Heparin Prophylaxis in Women with Thrombophilic Risk Factors --; Malignancy is not Associated with Decreased ADAMTS-13 Activity in Patients with Brain Tumors --; Analysis of Factor VIII RNA from Hemophilia A Patients with no Detectable Mutation in the Coding Regions --; FISH for Carrier Detection of Large Deletions in the Factor VIII Gene --; Homozygosity Mapping of a Second Gene Locus for Hereditary Combined Deficiency of Vitamin-K-Dependent Clotting Factors (FMFD) to Chromosome 16 --; First Case of Compound Heterozygosity in the Gamma-Glutamyl Carboxylase Gene Causing Combined Deficiency of all Vitamin-K-Dependent Blood Coagulation Factors --; Phosphatidylserine in the Neonatal and Adult Platelet Membrane: A Comparison --; Low Protein C, Tissue Factor Pathway Inhibitor, and Antithrombin Allow Sufficient Thrombin Generation in Neonatal Plasma.

The modern rehabilitation medicine is an important part of the comprehensive me- cal attendance of hemophiliacs. The necessary multidisciplinary team of specialists is available in a qualitative high-class rehabilitation hospital. Indispensable is the point that the coordinating medical specialist in Rehabilitation Medicine on site is skilled in the treatment of hemophiliacs. But he doesn't want and he can't replace the patient's hematologist. He is just the coordinator of the comprehensive team in the rehabilitation clinic. I hope I have shown that rehabilitation is an important topic for mos.

Thirty-third Hemophilia Symposium

Anesthesiology.

Critical care medicine.

Medicine.

edited by Inge Scharrer, Wolfgang Schramm.

Inge Scharrer

Wolfgang Schramm

[Book]

Y